^
    2ms
    XTX301-01: XTX301 in Patients with Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=358, Recruiting, Xilio Development, Inc. | Phase classification: P1 --> P1/2 | N=174 --> 358
    Phase classification • Enrollment change • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    XTX301
    9ms
    XTX301 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=174, Recruiting, Xilio Development, Inc. | N=94 --> 174
    Enrollment change • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    XTX301
    1year
    XTX301 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=94, Recruiting, Xilio Development, Inc.
    Trial completion date • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    XTX301
    1year
    XTX301, a tumor-activated Interleukin-12 has the potential to widen the therapeutic index of IL-12 treatment for solid tumors as evidenced by pre-clinical studies. (PubMed, Mol Cancer Ther)
    XTX301 was tolerated following four repeat doses up to 2.0 mg/kg in a non-human primate study; XTX301 exposures were substantially higher than those at the minimally efficacious dose in mice. Thus, XTX301 has the potential to achieve potent anti-tumor activity while widening the therapeutic index of IL-12 treatment and is currently being evaluated in a Phase 1 clinical trial.
    Preclinical • Journal
    |
    IFNG (Interferon, gamma)
    |
    XTX301
    over1year
    XTX301 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=94, Recruiting, Xilio Development, Inc. | Initiation date: Jan 2023 --> May 2023
    Trial initiation date • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    XTX301
    over1year
    A first-in-human study of XTX301, a masked, tumor-activated interleukin-12 (IL-12), in patients with advanced solid tumors. (ASCO 2023)
    Enrollment to the study is planned to begin in the first quarter of 2023. Clinical trial information: NCT05684965.
    Clinical • P1 data • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    XTX301
    almost2years
    XTX301 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=94, Recruiting, Xilio Development, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    XTX301
    almost2years
    XTX301 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=94, Not yet recruiting, Xilio Development, Inc.
    New P1 trial • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    XTX301